Citius Oncology, Inc. CTOR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s EPS (diluted)?
- Citius Oncology, Inc. (CTOR) reported EPS (diluted) of -$0.27 in Q1 2026.
- How has Citius Oncology, Inc.'s EPS (diluted) changed year-over-year?
- Citius Oncology, Inc.'s EPS (diluted) decreased by 145.5% year-over-year, from -$0.11 to -$0.27.
- What is the long-term trend for Citius Oncology, Inc.'s EPS (diluted)?
- Over 2 years (2023 to 2025), Citius Oncology, Inc.'s EPS (diluted) has grown at a 33.8% compound annual growth rate (CAGR), from -$0.19 to -$0.34.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.